ZVRA Stock Analysis: Buy, Sell, or Hold?
ZVRA - Zevra Therapeutics, Inc. Common Stock
$9.00
0.14 (1.58%)
▲
BUY
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Mar 10, 2026
Get Alerted When ZVRA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
2 traders called ZVRA this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ZVRA shows positive signals but monitor for confirmation. Market pricing in 0.8% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: ZVRA shows positive signals but monitor for confirmation. Market pricing in 0.8% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$2.29
Based on -21.3% avg growth
INTRINSIC VALUE TODAY
$1.42
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ZVRA is currently trading at $9.00, which is considered slightly high relative to its 30-day fair value range of $8.51 to $9.03. The stock's valuation (Forward PE: 14.3) is in line with its historical norms (14.0). At these levels, the market is pricing in 0.8% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, ZVRA is in a uptrend. Immediate support is located at $8.51, while resistance sits at $9.60.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $22.54 (+154.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ZVRA is in a uptrend. Immediate support is located at $8.51, while resistance sits at $9.60.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $22.54 (+154.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Fair Price Range
$8.51 -
$9.03
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.7%
All Signals
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 154.4% below Wall St target ($22.54)
- NEUTRAL: Market pricing in 0.8% annual earnings growth - fairly valued
Fair Price Analysis
30-Day Fair Range
$8.51 -
$9.03
Current vs Fair Value
SLIGHTLY HIGH
Expected Move (7 Days)
±$0.76
(8.5%)
Support & Resistance Levels
Support Level
$8.51
Resistance Level
$9.60
Current Trend
Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
14.29
Wall Street Target
$22.54
(+154.4%)
Revenue Growth (YoY)
605.4%
Profit Margin
41.9%
Valuation Premium vs History
+0.8% premium
PE vs Historical
14.3 vs 14.0
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.8%
(market-implied from PE analysis)
1-Year Target
$8.93
(+1%)
2-Year Target
$9.00
(+2%)
3-Year Target
$9.07
(+2%)
3-Yr Target (if PE normalizes)
(PE: 14→14)
PE COMPRESSION
$8.89
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: -46.6%)
$10.08
(+14%)
Base:
(SPY PE: 14.3, Growth: -46.6%)
$6.46
(-27%)
Bear:
(PE: 12.1, Growth: -46.6%)
$5.49
(-38%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (19x PE), but valuation improves significantly next year (14x PE) as earnings recover.
Trailing PE: 19.00 | Current EPS (TTM): $0.47
Bull Case
$12.96
(+46%)
Analyst growth 31.9%, PE expands to 20.9
Base Case
$11.78
(+33%)
Market implied 31.9%, PE stable at 19.0
Bear Case
$6.07
(-32%)
Severe decline -20.0%, PE contracts to 16.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Last updated: January 30, 2026 5:44 PM ET
Data refreshes hourly during market hours. Next update: 6:44 PM
Data refreshes hourly during market hours. Next update: 6:44 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ZVRA showing a specific setup today?
Insider Activity (6 Months)
2
Buys
1
Sells
+
Net
INSIDERS SELLING
Recent Transactions
Neil F Mcfarlane
SELL
19500 shares
2025-10-10
Tamara A Favorito
BUY
3175 shares
2025-09-12
John B Bode
BUY
5000 shares
2025-08-19
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$56 | 59 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$210 | 57 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$64 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$102 | 62 BUY |
|
ARVN
Arvinas Inc |
BUY
21 analysts |
$13 | 63 BUY |
Advanced ZVRA Option Strategies
Professional options setups generated by AI based on today's ZVRA price and gamma walls.
